Explore chapters and articles related to this topic
Antiasthma Agents during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
Chapter 11 covers antihistamine and expectorant use during pregnancy. The following relevant medications are included in Chapter 11: brompheniramine, cetirizine, chlorpheniramine, dexchlorpheniramine, diphenhydramine, hydroxyzine, loratadine, oxymetazoline, pheniramine, phenylephrine, pseudoephedrine, tripelennamine and triprolidine are generally considered safe for use during pregnancy. Some literature suggests that expectorants and mucolytics have efficacy for asthma treatment.
Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Pheniramine is a first generation antihistamine in the alkylamine class. It is used in some over-the-counter allergy as well as cold & flu products in combination with other drugs. Pheniramine’s use as an anti-allergy medication for hay fever, rhinitis, allergic dermatoses, and pruritus has largely been supplanted by second generation antihistamines. It is also used in eye drops for the treatment of allergic conjunctivitis. In pharmaceutical products, pheniramine is employed as pheniramine maleate (CAS number 132-20-7, EC number 205-051-4, molecular formula C20H24N2O4) (1).
Long-term experience with rituximab therapy for treatment-resistant moderate-to-severe pemphigus
Published in Journal of Dermatological Treatment, 2022
Burçin Cansu Bozca, Aslı Bilgiç, Soner Uzun
The RTX therapy had been administered to patients with pemphigus if they (i) were unable to achieve remission despite receiving the maximum tolerable dose of methylprednisolone (MP), (ii) had corticosteroid (CS)-dependent disease (i.e. reduction of the CS dose was not possible), or (iii) had serious complications related to CS and/or immunosuppressive therapies. Based on our previous report, we administered premedication (1 g oral paracetamol and IV pheniramine maleate 45.5 mg/2 ml and 100 mg methylprednisolone administered 1 h prior to each infusion) before the RTX infusion and prophylaxis against Pneumocystis jirovecii (Trimethoprim–sulfamethoxazole from the initiation of each RTX cycle and continuing for the next 6 months as a dose of two forte tablets per week) (28). Patients had been considered ineligible for RTX therapy of they (i) were pregnant, (ii) were breastfeeding, (iii) had a history of murine protein sensitivity, (iv) had a history of any malignancy, (v) had active and severe infections (including tuberculosis, sepsis, opportunistic infections, and uncontrolled hepatitis), or (vi) had severe uncontrolled cardiac disease.
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
Published in Journal of Chemotherapy, 2022
Bahar Uncu Ulu, Mehmet Sinan Dal, İpek Yönal Hindilerden, Olga Meltem Akay, Özgür Mehtap, Nurhilal Büyükkurt, Fehmi Hindilerden, Ahmet Kürşad Güneş, Tuğçe Nur Yiğenoğlu, Semih Başcı, Merih Kızıl Çakar, Didar Yanardağ Açık, Serdal Korkmaz, Turgay Ulaş, Gülsüm Özet, Burhan Ferhanoğlu, Meliha Nalçacı, Fevzi Altuntaş
Grade 3/4 haematological and non-haematological toxicities were defined according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTC) version 4.0. Hematological toxicities were evaluated in the first week of BvB treatment. On the first day of the treatment, 30 min before the onset of Bv, 8 mg dexamethasone and 45.5 mg pheniramine maleate were administered as pre-medications for the patients. No pre-medication was administered before B on the second day of treatment. Antiemetic treatment was administered in case of nausea symptoms. Neutropenic patients received growth factor support during treatment. The response evaluation was assessed using PET/CT. Response evaluation was performed after at least two cycles of combination treatment. This assessment was repeated every two cycles following more than two cycles of treatment. PET-CT scans were evaluated four to six weeks after treatment for response assessment according to the Deauville five-point scale [15].
Pitolisant for treating patients with narcolepsy
Published in Expert Review of Clinical Pharmacology, 2020
Concomitant administration of pitolisant with strong CYP2D6 inhibitors (such as paroxetine, fluoxetine, bupropion) increases pitolisant exposure by 2.2 fold. Concomitant use of pitolisant with strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin) decreases exposure of pitolisant by 50% [12,13]. Pitolisant increases the levels of histamine in the brain, therefore, H1 receptor antagonists that cross the blood-brain barrier (such pheniramine maleate, diphenhydramine, promethazine, imipramine, clomipramine, mirtazapine) may reduce the effectiveness of pitolisant [12,13]. Concomitant use of drugs that prolong the QT interval (such as quinidine, procainamide, disopyramide; amiodarone, sotalol; ziprasidone, chlorpromazine, thioridazine; moxifloxacin) may add to the QT effects of pitolisant and increase the risk of cardiac arrhythmia [12,13].